IMV Inc.

  • Home
  • About Us
    • Overview
    • Management Team
    • Board of Directors
  • Careers
    • Overview
    • Life at IMV
  • The DPX™ Platform
    • Overview
    • Scientific Publications & Posters
  • Clinical Pipeline
    • Overview
    • Maveropepimut-S
    • DPX-RSV
    • DPX-COVID-19
    • Clinical Trials
  • News & Events
    • Press Releases
    • Events
    • Email Alerts
    • Annual General and Special Shareholders Meeting
  • Investors
    • Overview
    • Press Releases
    • Events, Webcasts & Presentations
    • Financial Info
    • Stock Data
    • Filings
    • Governance
    • Contact Us
    • FAQ
  • Contact

Press Releases

Investors

Investors

  • Overview
  • Press Releases
  • Events, Webcasts & Presentations
    • Overview
    • Presentations
    • Scientific Publications & Posters
    • Email Alerts
  • Financial Info
    • Financial Results
    • Tax Info
    • Proxy Info
    • Stock Option Plan
    • Deferred Share Unit Plan
  • Stock Data
    • NASDAQ: IMV
    • TSX: IMV
    • Analyst Coverage
  • Filings
    • SEC Filings
    • SEDAR
  • Governance
    • Board of Directors
    • Board Committees
    • Governance Documents
  • Contact Us
  • FAQ
Mar 10, 2022 7:05am EST

IMV Inc. to Announce Fourth Quarter and Fiscal Year 2021 Results and Host a Conference Call and Webcast on March 17, 2022

Mar 09, 2022 7:05am EST

IMV to Showcase its DPX® Delivery Technology in Two Presentations at the AACR Annual Meeting 2022

Feb 17, 2022 7:05am EST

IMV to Host a Webcast to Highlight its Immune-Educating DPX® Platform

Jan 12, 2022 7:05am EST

IMV Announces First Patient Dosed in the VITALIZE Phase 2B Clinical Study Evaluating its Lead Compound, MVP-S, in Combination with KEYTRUDA® (pembrolizumab) in Patients with r/r DLBCL

Jan 05, 2022 7:05am EST

IMV Inc. to Present at Two Upcoming Investor Events

Dec 22, 2021 7:05am EST

IMV Appoints Andrew Hall as Chief Executive Officer

Dec 21, 2021 7:05am EST

IMV Announces Finalization of the Basket Clinical Study in Collaboration with Merck and Reveals Promising Top Line Data from the Bladder and MSI-High Cohorts

Dec 20, 2021 7:05am EST

IMV Strengthens its Financial Position with the Completion of a US$25 Million Long-Term Debt Facility

Dec 02, 2021 7:05am EST

Role of B Cells Induced by IMV’s Lead Compound in Patients with Ovarian Cancer to be Showcased at the ESMO-IO Congress

Nov 30, 2021 7:05am EST

IMV Announces First Patient Dosed in Phase 1b Clinical Study Evaluating its Lead Compound in Patients with Breast Cancer

RSS
  • Prev
  • 1
  • 2
  • 3
  • 4
  • 5
  • 6
  • 7
  • 8
  • 9
  • 10
  • ...40
  • Next
  • Email Alerts
  • Contacts
  • RSS News Feed
IMV Inc.
About Us Careers The DPX™ Platform Clinical Pipeline News & Events Investors Contact
Twitter LinkedIn Youtube
© 2022 IMV Inc. All Rights Reserved.
Privacy Policy Terms of Use Sitemap